Best practices in phase III clinical trials on DMTs for multiple sclerosis: a systematic analysis and appraisal of published trials

Conclusions
RCTs for DMTs in MS have relevant and frequent limitations. These should be addressed to enhance their quality, transparency and external validity.

Source: Journal of Neurology, Neurosurgery and Psychiatry - March 13, 2024 Category: Neurosurgery Authors: Mascarenas-Garcia, M., Rivero-de-Aguilar, A., Perez-Rios, M., Ruano-Ravina, A., Llaneza-Gonzalez, M. A., Candal-Pedreira, C., Rey-Brandariz, J., Varela-Lema, L. Tags: Multiple sclerosis Source Type: research